Thats a unique idea.You should consider the following idea to enhance your idea so that it would impact uniquely: Objectives: To compare the risk of infection for rheumatoid arthritis (RA) patients who took etanercept or adalimumab medication in a nationwide population. Methods: RA patients who took etanercept or adalimumab re identified in the Taiwan's National Health Insurance Research Database. The composite outcome of serious infections, including hospitalization for infection, reception of an antimicrobial injection, and tuberculosis re follod for 365 days. A Kaplan-Meier survival curve with a log-rank test and Cox proportional hazards regression re used to compare risks of infection beten the two cohorts of tumor necrosis factor (TNF)-@a antagonists users. Hazard ratios (HRs) re obtained and adjusted with propensity scores and clinical factors. Sensitivity analyses and subgroup analyses re also performed. Results: In total, 1660 incident etanercept users and 484 incident adalimumab users re eligible for the analysis. The unadjusted HR for infection of the etanercept users was significantly higher than that of the adalimumab users (HR: 1.93; 95% confidence interval (CI): 1.09-3.42; p=0.024). The HRs re 2.04 (95% CI: 1.14-3.65; p=0.016) and 2.02 (95% CI: 1.13-3.61; p=0.018) after adjusting for propensity scores and for propensity scores in addition to clinical factors, respectively. The subgroup analyses revealed that HRs for composite infection was significantly higher in patient subgroups of older age, female, as ll as patients who did not have DM, COPD, and hospitalization history at the baseline. Conclusion: In this head-to-head cohort study involving a nationwide population of patients with RA, etanercept users demonstrated a higher risk of infection than adalimumab users. Results of this study suggest the possible existence of an intra-class difference in infection risk among TNF-@a antagonists.
['Yi Chun Chiang', 'Li Na Kuo', 'Yu Hsuan Yen', 'Chao Hsiun Tang', 'Hsiang Yin Chen']
I am writing a research paper on a idea Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab
[{"from": "human", "value": "I am writing a research paper on a idea Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab"}, {"from": "gpt", "value": "Thats a unique idea.You should consider the following idea to enhance your idea so that it would impact uniquely: Objectives: To compare the risk of infection for rheumatoid arthritis (RA) patients who took etanercept or adalimumab medication in a nationwide population. Methods: RA patients who took etanercept or adalimumab re identified in the Taiwan's National Health Insurance Research Database. The composite outcome of serious infections, including hospitalization for infection, reception of an antimicrobial injection, and tuberculosis re follod for 365 days. A Kaplan-Meier survival curve with a log-rank test and Cox proportional hazards regression re used to compare risks of infection beten the two cohorts of tumor necrosis factor (TNF)-@a antagonists users. Hazard ratios (HRs) re obtained and adjusted with propensity scores and clinical factors. Sensitivity analyses and subgroup analyses re also performed. Results: In total, 1660 incident etanercept users and 484 incident adalimumab users re eligible for the analysis. The unadjusted HR for infection of the etanercept users was significantly higher than that of the adalimumab users (HR: 1.93; 95% confidence interval (CI): 1.09-3.42; p=0.024). The HRs re 2.04 (95% CI: 1.14-3.65; p=0.016) and 2.02 (95% CI: 1.13-3.61; p=0.018) after adjusting for propensity scores and for propensity scores in addition to clinical factors, respectively. The subgroup analyses revealed that HRs for composite infection was significantly higher in patient subgroups of older age, female, as ll as patients who did not have DM, COPD, and hospitalization history at the baseline. Conclusion: In this head-to-head cohort study involving a nationwide population of patients with RA, etanercept users demonstrated a higher risk of infection than adalimumab users. Results of this study suggest the possible existence of an intra-class difference in infection risk among TNF-@a antagonists."}]